SynthesisInternational journal of surgery (London, England)2025
Efficacy and safety of preoperative biliary drainage in patients with Hilar Cholangiocarcinoma: a systematic review and meta-analysis.
Synthesis in International journal of surgery (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Determinants and survival benefits of achieving textbook outcome for intrahepatic cholangiocarcinoma in the era of neoadjuvant therapy.Frontiers in oncology · 2026Article
- Review
- Advances in Endoscopic Diagnosis and Management of Cholangiocarcinoma.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreoperative biliary drainage (PBD) has been proposed as a strategy to manage the complications associated with biliary obstruction in hilar cholangiocarcinoma patients. However, the efficacy and safety of PBD in remain controversial, even in clinical guidelines. This meta-analysis aimed to provide a comprehensive evaluation of the efficacy and safety of PBD in patients with hilar cholangiocarcinoma.
methodsPubMed, Medline, EMBASE, Cochrane Library, and registers were screened to investigate the efficacy and safety of PBD in patients with hilar cholangiocarcinoma. The search timeframe was set before December 2024. Mortality, morbidity, and postoperative infection served as the primary outcomes, while the secondary outcomes included transfusion, operative time, operative bloody loss, intraabdominal abscess, intraabdominal bleeding, leakage (bile leak or anastomotic leakage), hepatic insufficiency, renal insufficiency, second laparotomy, total hospital stay, cholangitis. Studies were evaluated for quality by Newcastle-Ottawa scale. Data were pooled as odds ratio ( OR ) or standard mean difference ( SMD ).
resultsOur meta-analysis of 21 studies (3059 patients) showed that PBD reduced hepatic insufficiency ( OR = 0.38, 95% CI = 0.16-0.90, P = 0.03, I 2 = 69%) but increased risks of long term follow up mortality ( OR = 1.90, 95% CI = 1.02-3.56, P = 0.04, I 2 = 0%), morbidity ( OR = 1.47, 95% CI = 1.12-1.92, P = 0.01, I 2 = 52%), postoperative infection ( OR = 2.46, 95% CI = 1.17-5.18, P = 0.02, I 2 = 69%), transfusion ( OR = 1.39, 95% CI = 1.06-1.81, P = 0.02, I 2 = 49%), leakage ( OR = 1.67, 95% CI = 1.08-2.60, P = 0.02, I 2 = 44%), cholangitis ( OR = 6.40, 95% CI = 1.75-23.48, P = 0.01, I 2 = 51%), and prolonged hospital stay ( SMD = 0.53, 95% CI = 0.06-0.99, P = 0.03, I 2 = 87%). There was no difference in overall mortality, operative time, blood loss, or other complications ( P > 0.05). Subgroup analysis showed that differences in some outcomes lost significance with higher bilirubin levels, fewer PBD cases, studies published after 2010, and strictly select PBD patients ( P < 0.05).
conclusionsRoutine PBD cannot be recommended but it tends to be a better choice in patients with average initial bilirubin above 218.75 μmol/L, portal vein embolization and malnutrition. Further multicenter randomized studies should address the potential advantages of PBD over NPBD, identify clear patient selection criteria, and determine the optimal bilirubin threshold for PBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.